Retrospective Analysis of Trabectedin Therapy for Soft Tissue Sarcoma

Area of Science:

• Oncology
• Pharmacology

Background:

• Trabectedin is a synthetic antineoplastic agent.
• It is approved in Japan for advanced soft tissue sarcoma (STS).

Purpose of the Study:

• To evaluate the efficacy and safety of the Japan-approved dose of trabectedin for advanced STS.

Main Methods:

• Retrospective review of 38 patients with advanced STS.
• Patients received salvage chemotherapy with trabectedin.

Main Results:

• Overall response rate was 16% (5/38 patients).
• Disease control rate was 67% (20/38 patients).
• Median progression-free survival was 7.3 months; median overall survival was 17.8 months.
• Common grade 3-4 adverse events included elevated transaminases and neutropenia.

Conclusions:

• The Japan-approved dose (1.2 mg/m²) demonstrated efficacy comparable to the Western dose (1.5 mg/m²).
• Trabectedin is a potential treatment option for advanced STS in Japan across histological subtypes.